Lataa...
Effects of food on the pharmacokinetics of ponatinib in healthy subjects
WHAT IS KNOWN AND OBJECTIVE: Ponatinib is a potent oral tyrosine kinase inhibitor with activity against BCR-ABL, the primary driver of chronic myeloid leukaemia and Philadelphia chromosome–positive acute lymphoblastic leukaemia. This single-centre, single-dose, randomized, open-label, three-period c...
Tallennettuna:
| Julkaisussa: | J Clin Pharm Ther |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BlackWell Publishing Ltd
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4286001/ https://ncbi.nlm.nih.gov/pubmed/23888935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcpt.12082 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|